Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 687

1.

Proteasome inhibitor therapy in multiple myeloma.

Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC.

Mol Cancer Ther. 2005 Apr;4(4):686-92. Review.

2.

Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.

Bladé J, Cibeira MT, Rosiñol L.

Acta Oncol. 2005;44(5):440-8. Review.

PMID:
16118077
3.

Current status of bortezomib in the treatment of multiple myeloma.

Cavo M.

Curr Hematol Malig Rep. 2007 May;2(2):128-37. doi: 10.1007/s11899-007-0018-y. Review.

PMID:
20425361
4.

The proteasome: a novel target for anticancer therapy.

Montagut C, Rovira A, Albanell J.

Clin Transl Oncol. 2006 May;8(5):313-7. Review.

PMID:
16760005
5.
6.

Proteasome inhibition for treatment of multiple myeloma: clinical update.

Stadtmauer EA.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S10-5. Review.

PMID:
19795531
7.

Proteasome inhibition in multiple myeloma.

Kropff M, Bisping G, Wenning D, Berdel WE, Kienast J.

Eur J Cancer. 2006 Jul;42(11):1623-39. Epub 2006 Jul 3. Review.

PMID:
16820291
8.

Bortezomib and its role in the management of patients with multiple myeloma.

Orlowski RZ.

Expert Rev Anticancer Ther. 2004 Apr;4(2):171-9. Review.

PMID:
15056047
9.

Moving disease biology from the lab to the clinic.

Anderson KC.

Cancer. 2003 Feb 1;97(3 Suppl):796-801.

10.

Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.

Ludwig H, Khayat D, Giaccone G, Facon T.

Cancer. 2005 Nov 1;104(9):1794-807. Review.

11.

Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.

Richardson PG, Hideshima T, Anderson KC.

Cancer Control. 2003 Sep-Oct;10(5):361-9. Review.

PMID:
14581890
12.

Proteasome inhibitors in cancer therapy.

Orlowski RZ.

Methods Mol Biol. 2005;301:339-50. Review.

PMID:
15917644
13.

[Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].

Takatoku M, Noborio-Hatano K, Takahashi S, Kikuchi S, Mori M, Muroi K, Komatsu N, Ozawa K.

Rinsho Ketsueki. 2004 Feb;45(2):144-8. Japanese.

PMID:
15045823
14.

Proteasome inhibition: a new approach for the treatment of malignancies.

Spano JP, Bay JO, Blay JY, Rixe O.

Bull Cancer. 2005 Nov;92(11):E61-6, 945-52. Review. English, French.

15.

Bortezomib: a novel therapy approved for multiple myeloma.

Richardson PG, Anderson KC.

Clin Adv Hematol Oncol. 2003 Oct;1(10):596-600. Review.

PMID:
16258456
16.

Bortezomib for multiple myeloma.

Popat R, Joel S, Oakervee H, Cavenagh J.

Expert Opin Pharmacother. 2006 Jul;7(10):1337-46. Review.

PMID:
16805719
17.

Bortezomib in multiple myeloma.

Mateos MV, San Miguel JF.

Best Pract Res Clin Haematol. 2007 Dec;20(4):701-15. Review.

PMID:
18070714
18.

Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.

von Metzler I, Heider U, Mieth M, Lamottke B, Kaiser M, Jakob C, Sezer O.

Exp Cell Res. 2009 Aug 15;315(14):2471-8. doi: 10.1016/j.yexcr.2009.04.019. Epub 2009 May 3.

PMID:
19410573
19.

New drugs for myeloma.

Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K.

Oncologist. 2007 Jun;12(6):664-89. Review.

20.

Proteasome inhibition and multiple myeloma.

Kanagasabaphy P, Morgan GJ, Davies FE.

Curr Opin Investig Drugs. 2007 Jun;8(6):447-51. Review.

PMID:
17621873

Supplemental Content

Support Center